Novo Nordisk Pharma and Hiroshima Prefecture Sign Partnership Agreement to Extend Healthy Life Expectancy
Novo Nordisk Pharma entered into a partnership agreement with Hiroshima Prefecture on April 13, 2026, aimed at extending healthy life expectancy. With the participation of Chugoku Electric Power Co., the initiative will promote the correct understanding, early detection, and proper treatment of obesity and related chronic diseases through public-private collaboration.
📋 Article Processing Timeline
- 📰 Published: April 13, 2026 at 22:30
- 🔍 Collected: April 13, 2026 at 16:35
- 🤖 AI Analyzed: April 19, 2026 at 20:29 (147h 53m after Collected)
On April 13, Novo Nordisk Pharma Ltd. (President: Keisuke Kotani, Headquarters: Chiyoda-ku, Tokyo) signed a 'Partnership and Cooperation Agreement on the Extension of Healthy Life Expectancy between Hiroshima Prefecture and Novo Nordisk Pharma Ltd.' with Hiroshima Prefecture (Governor: Mika Yokota).
This agreement is a public-private partnership initiative aimed at extending the healthy life expectancy of Hiroshima Prefecture residents by promoting environmental improvements that lead to the prevention, early detection, and appropriate medical care of chronic diseases. Centered in Hiroshima Prefecture and with the participation of Chugoku Electric Power Co., Inc., the prefecture and companies will collaborate to advance comprehensive approaches to chronic diseases in the region.
As one of the specific initiatives, measures will be implemented to promote a correct understanding of obesity and encourage appropriate medical consultations. Using Hiroshima Prefecture as a hub, and utilizing the health checkup opportunities of partner companies, we aim to promote treatment by encouraging employees who are subjects for obesity treatment to seek medical attention.
Novo Nordisk Pharma Ltd. has been contributing to the promotion of chronic disease countermeasures and health improvement measures in regions by collaborating with local governments nationwide.
Under this agreement as well, based on a framework where the prefecture and companies collaborate, we will steadily roll out chronic disease countermeasures that contribute to the extension of healthy life expectancy in Hiroshima Prefecture. As part of this, we will advance appropriate responses to related diseases including obesity, aiming to establish a sustainable regional model.
Overview of the 'Partnership and Cooperation Agreement on the Extension of Healthy Life Expectancy between Hiroshima Prefecture and Novo Nordisk Pharma Ltd.'
■ Purpose
Through close mutual cooperation and collaboration between the Hiroshima Prefectural Government and Novo Nordisk Pharma Ltd., to spread initiatives related to extending the healthy life expectancy of prefecture residents throughout society as a whole.
■ Matters of Cooperation and Collaboration
(1) Matters related to the dissemination and enlightenment of correct knowledge regarding obesity / obesity disease
(2) Matters related to initiatives promoting early detection, early diagnosis, and early treatment of obesity disease
(3) Matters related to providing and disseminating appropriate information on related chronic diseases originating from obesity disease (cardiovascular diseases, diabetes, *MASLD/MASH, etc.)
(4) Other matters to widely address health promotion for prefecture residents across society and create an environment where everyone can live vigorously and with peace of mind
*Metabolic dysfunction-associated steatotic liver disease / Metabolic dysfunction-associated steatohepatitis
■ Project Participating Partner Company
Chugoku Electric Power Co., Inc.
■ Roles
Novo Nordisk Pharma Ltd.
- Broad disease awareness for prefecture residents and healthcare professionals
- Dissemination of good practices in Hiroshima Prefecture and nationwide promotion
Hiroshima Prefecture
- Broad disease awareness for prefecture residents
- Formulation and evaluation of obesity disease countermeasure plans
- Coordination with medical associations and medical institutions
Chugoku Electric Power Co., Inc.
- Implementation of consultation recommendations for target individuals
- Internal awareness activities regarding the importance of maintaining an appropriate weight and obesity disease
About Obesity and Obesity Disease
In Japan, 'obesity' is defined as a state of excessive fat accumulation in adipose tissue with a Body Mass Index (BMI) of 25 or higher. 'Obesity disease' is defined as a pathology where obesity is present, and it is accompanied by or predicted to be accompanied by health disorders* caused by or related to obesity, medically requiring weight loss.
*Health disorders required for the diagnosis of obesity disease: 1. Impaired glucose tolerance (type 2 diabetes, abnormal glucose tolerance, etc.), 2. Dyslipidemia, 3. Hypertension, 4. Hyperuricemia/Gout, 5. Coronary artery disease, 6. Cerebral infarction/Transient ischemic attack, 7. Non-alcoholic fatty liver disease, 8. Menstrual abnormalities/Female infertility, 9. Obstructive sleep apnea syndrome/Obesity hypoventilation syndrome, 10. Orthopedic diseases (Osteoarthritis: knee/hip/finger joints, Spondylosis deformans), 11. Obesity-related kidney disease
About 'NovoCare™ Knowing Obesity Disease'
'NovoCare™ Knowing Obesity Disease' is a website operated by Novo Nordisk Pharma Ltd., under the concept of 'understanding obesity disease correctly', to support individuals living with obesity disease, their families, and those aiming for obesity improvement. It features various contents such as articles explaining obesity disease and various factors of obesity, an obesity literacy test where you can learn about obesity disease with quizzes, and interview articles of people living with obesity and obesity disease. (https://www.novocare.jp)
About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is...
This agreement is a public-private partnership initiative aimed at extending the healthy life expectancy of Hiroshima Prefecture residents by promoting environmental improvements that lead to the prevention, early detection, and appropriate medical care of chronic diseases. Centered in Hiroshima Prefecture and with the participation of Chugoku Electric Power Co., Inc., the prefecture and companies will collaborate to advance comprehensive approaches to chronic diseases in the region.
As one of the specific initiatives, measures will be implemented to promote a correct understanding of obesity and encourage appropriate medical consultations. Using Hiroshima Prefecture as a hub, and utilizing the health checkup opportunities of partner companies, we aim to promote treatment by encouraging employees who are subjects for obesity treatment to seek medical attention.
Novo Nordisk Pharma Ltd. has been contributing to the promotion of chronic disease countermeasures and health improvement measures in regions by collaborating with local governments nationwide.
Under this agreement as well, based on a framework where the prefecture and companies collaborate, we will steadily roll out chronic disease countermeasures that contribute to the extension of healthy life expectancy in Hiroshima Prefecture. As part of this, we will advance appropriate responses to related diseases including obesity, aiming to establish a sustainable regional model.
Overview of the 'Partnership and Cooperation Agreement on the Extension of Healthy Life Expectancy between Hiroshima Prefecture and Novo Nordisk Pharma Ltd.'
■ Purpose
Through close mutual cooperation and collaboration between the Hiroshima Prefectural Government and Novo Nordisk Pharma Ltd., to spread initiatives related to extending the healthy life expectancy of prefecture residents throughout society as a whole.
■ Matters of Cooperation and Collaboration
(1) Matters related to the dissemination and enlightenment of correct knowledge regarding obesity / obesity disease
(2) Matters related to initiatives promoting early detection, early diagnosis, and early treatment of obesity disease
(3) Matters related to providing and disseminating appropriate information on related chronic diseases originating from obesity disease (cardiovascular diseases, diabetes, *MASLD/MASH, etc.)
(4) Other matters to widely address health promotion for prefecture residents across society and create an environment where everyone can live vigorously and with peace of mind
*Metabolic dysfunction-associated steatotic liver disease / Metabolic dysfunction-associated steatohepatitis
■ Project Participating Partner Company
Chugoku Electric Power Co., Inc.
■ Roles
Novo Nordisk Pharma Ltd.
- Broad disease awareness for prefecture residents and healthcare professionals
- Dissemination of good practices in Hiroshima Prefecture and nationwide promotion
Hiroshima Prefecture
- Broad disease awareness for prefecture residents
- Formulation and evaluation of obesity disease countermeasure plans
- Coordination with medical associations and medical institutions
Chugoku Electric Power Co., Inc.
- Implementation of consultation recommendations for target individuals
- Internal awareness activities regarding the importance of maintaining an appropriate weight and obesity disease
About Obesity and Obesity Disease
In Japan, 'obesity' is defined as a state of excessive fat accumulation in adipose tissue with a Body Mass Index (BMI) of 25 or higher. 'Obesity disease' is defined as a pathology where obesity is present, and it is accompanied by or predicted to be accompanied by health disorders* caused by or related to obesity, medically requiring weight loss.
*Health disorders required for the diagnosis of obesity disease: 1. Impaired glucose tolerance (type 2 diabetes, abnormal glucose tolerance, etc.), 2. Dyslipidemia, 3. Hypertension, 4. Hyperuricemia/Gout, 5. Coronary artery disease, 6. Cerebral infarction/Transient ischemic attack, 7. Non-alcoholic fatty liver disease, 8. Menstrual abnormalities/Female infertility, 9. Obstructive sleep apnea syndrome/Obesity hypoventilation syndrome, 10. Orthopedic diseases (Osteoarthritis: knee/hip/finger joints, Spondylosis deformans), 11. Obesity-related kidney disease
About 'NovoCare™ Knowing Obesity Disease'
'NovoCare™ Knowing Obesity Disease' is a website operated by Novo Nordisk Pharma Ltd., under the concept of 'understanding obesity disease correctly', to support individuals living with obesity disease, their families, and those aiming for obesity improvement. It features various contents such as articles explaining obesity disease and various factors of obesity, an obesity literacy test where you can learn about obesity disease with quizzes, and interview articles of people living with obesity and obesity disease. (https://www.novocare.jp)
About Novo Nordisk
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is...